Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops kinase inhibitor treatments for various type of cancer diseases including gastrointestinal, stromal tumors, advance systemic mastocytosis, gliomas, and other solid tumors. Deciphera Pharmaceuticals serves patients globally.
Website: deciphera.com



Growth: Good revenue growth rate 36.4%, there is slowdown compared to average historical growth rates 46.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -116.7%. On average the margin is improving steadily. Gross margin is high, +91.8%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -13.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 153.1% higher than minimum and 0.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.9x by EV / Sales multiple

Key Financials (Download financials)

Ticker: DCPH
Share price, USD:  (0.0%)25.59
year average price 25.59  


year start price 25.59 2025-07-26

max close price 25.59 2025-07-26

min close price 25.59 2025-07-26

current price 25.59 2026-07-25
Common stocks: 86 702 025

Dividend Yield:  0.0%
EV / Sales: 12.4x
Margin (EBITDA LTM / Revenue): -116.7%
Fundamental value created in LTM:
Market Cap ($m): 2 219
Net Debt ($m): -66
EV (Enterprise Value): 2 153
Price to Book: 7.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-17businesswire.com

Deciphera Announces the Opening of a New Office in Zug, Switzerland

2025-10-18businesswire.com

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

2025-02-14businesswire.com

U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

2024-05-23zacks.com

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

2024-05-10Zacks Investment Research

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

2024-05-10Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

2024-04-30Reuters

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

2024-04-29Invezz

ONO to buy Deciphera Pharmaceuticals at a huge premium

2024-04-29InvestorPlace

Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?

2024-04-29Barrons

Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-10 2023-10-30 2023-08-09 2023-05-03 2022-11-03
acceptedDate 2024-05-10 07:27:06 2024-02-07 07:11:52 2023-10-30 07:11:54 2023-08-09 07:09:53 2023-05-03 07:10:05 2023-02-07 07:17:16 2022-11-03 07:09:23 2022-02-08 17:02:30 2021-02-09 16:09:37 2020-03-09 16:08:32
calendarYear 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
revenue 45M 163M 43M 38M 33M 134M 36M 96M 42M 25M
costOfRevenue 4M 4M 1M 173 000 488 000 9M 3M 3M 225 000 830 000
grossProfit 41M 160M 42M 38M 33M 125M 33M 93M 42M 24M
grossProfitRatio 0.918 0.97 0.995 0.985 0.907
researchAndDevelopmentExpenses 57M 234M 62M 58M 55M 188M 47M 257M 199M 158M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 33M 136M 33M 33M 31M 120M 30M 136M 114M 68M
otherExpenses 0 0 0 0 0 0 0 0 0 0
operatingExpenses 90M 371M 96M 91M 86M 308M 78M 393M 313M 226M
costAndExpenses 94M 374M 97M 91M 87M 317M 81M 396M 313M 226M
interestIncome 4M 16M 4M 4M 4M 5M 2M 113 000 5M 9M
interestExpense 0 0 0 0 -4M 5M 2M 0 0 67 000
depreciationAndAmortization 2M 2M 465 000 571 000 608 000 3M 742 000 3M 7M 9M
ebitda -47M -209M -54M -52M -53M -171M -44M -297M -264M -184M
ebitdaratio -1.05 -1.24 -1.363 -1.592 -1.227
operatingIncome -49M -211M -54M -53M -53M -183M -45M -300M -271M -201M
operatingIncomeRatio -1.086 -1.24 -1.378 -1.592 -1.248
totalOtherIncomeExpensesNet 4M 16M 4M 4M 4M 5M 2M 113 000 5M 8M
incomeBeforeTax -45M -195M -50M -49M -50M -178M -43M -300M -266M -192M
incomeBeforeTaxRatio -1.002 -1.145 -1.268 -1.483 -1.197
incomeTaxExpense 0 431 000 -465 000 0 -608 000 722 000 -4M -3M 0 -763 000
netIncome -45M -195M -50M -49M -50M -179M -39M -297M -266M -191M
netIncomeRatio -1.002 -1.145 -1.268 -1.483 -1.094
eps -0.52 -2.29 -0.58 -0.57 -0.6 -2.37 -0.5 -5.11 -4.78 -4.47
epsdiluted -0.52 -0.58 -0.57 -0.6 -0.5
weightedAverageShsOut 87M 85M 86M 85M 83M 76M 78M 58M 56M 43M
weightedAverageShsOutDil 87M 85M 86M 85M 83M 76M 78M 58M 56M 43M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2024-02-07 2023-02-07 2022-02-08 2021-02-09 2020-03-09
fiscalYear 2023 2022 2021 2020 2019
netInterestIncome 16M 0 113 000 5M 8M
ebit -211M -174M -300M -271M -192M
nonOperatingIncomeExcludingInterest 0 -9M 0 0 -9M
netIncomeFromContinuingOperations -195M -179M -297M -266M -191M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -195M -179M -297M -266M -191M
epsDiluted -2.29 -2.37 -5.11 -4.78 -4.47

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-10 2023-10-30 2023-08-09 2023-05-03 2022-11-03
acceptedDate 2024-05-10 07:27:06 2024-02-07 07:11:52 2023-10-30 07:11:54 2023-08-09 07:09:53 2023-05-03 07:10:05 2023-02-07 07:17:16 2022-11-03 07:09:23 2022-02-08 17:02:30 2021-02-09 16:09:37 2020-03-09 16:08:32
calendarYear 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 91M 84M 108M 81M 115M 65M 83M 87M 136M 120M
shortTermInvestments 181M 223M 231M 247M 284M 260M 282M 199M 416M 459M
cashAndShortTermInvestments 273M 306M 339M 329M 399M 324M 365M 286M 552M 580M
netReceivables 33M 32M 28M 23M 22M 22M 23M 21M 14M 0
inventory 21M 21M 27M 25M 26M 21M 19M 14M 6M 0
otherCurrentAssets 24M 22M 24M 28M 30M 25M 14M 19M 12M 14M
totalCurrentAssets 350M 381M 418M 405M 476M 393M 421M 339M 584M 593M
propertyPlantEquipmentNet 36M 37M 39M 41M 42M 43M 45M 45M 46M 27M
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0
longTermInvestments 35M 47M 38M 61M 28M 15M 7M 42M 9M 2M
taxAssets 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 8M 3M 3M 3M 3M 3M 3M 3M 0
totalNonCurrentAssets 71M 92M 80M 105M 73M 61M 55M 90M 58M 29M
otherAssets 0 0 0 0 0 0 0 0 0 0
totalAssets 421M 474M 498M 510M 549M 454M 476M 429M 642M 622M
accountPayables 19M 26M 21M 18M 20M 19M 13M 13M 12M 20M
shortTermDebt 4M 4M 3M 3M 3M 3M 3M 3M 2M 2M
taxPayables 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 68M 63M 56M 0 0 0 80M 0 0
otherCurrentLiabilities 60M 2M 5M 3M 61M 65M 59M 1M 55M 39M
totalCurrentLiabilities 83M 100M 93M 81M 84M 86M 75M 97M 70M 60M
longTermDebt 21M 22M 23M 24M 25M 26M 27M 28M 29M 16M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 11M 0 0 0
totalNonCurrentLiabilities 21M 22M 23M 24M 25M 26M 27M 28M 29M 16M
otherLiabilities 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 27M 28M 28M 0 30M 0 0 0
totalLiabilities 105M 123M 116M 105M 109M 112M 102M 125M 99M 76M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 821 000 805 000 799 000 788 000 785 000 676 000 674 000 585 000 576 000 516 000
retainedEarnings -1 473M -1 428M -1 381M -1 332M -1 283M -1 233M -1 187M -1 054M -754M -488M
accumulatedOtherComprehensiveIncomeLoss 98 000 577 000 -896 000 -967 000 -181 000 -983 000 -2M 51 000 11 000 111 000
othertotalStockholdersEquity 1 789M 1 763M 1 736M 1 722M 1 563M
totalStockholdersEquity 316M 351M 382M 404M 440M 342M 374M 305M 544M 546M
totalEquity 316M 351M 382M 404M 440M 342M 374M 305M 544M 546M
totalLiabilitiesAndStockholdersEquity 421M 498M 510M 549M 476M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 421M 474M 498M 510M 549M 454M 476M 429M 642M 622M
totalInvestments 216M 269M 269M 308M 312M 274M 289M 241M 425M 461M
totalDebt 25M 26M 27M 28M 28M 29M 30M 31M 31M 18M
netDebt -66M -58M -81M -54M -86M -36M -53M -56M -105M -103M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2024-02-07 2023-02-07 2022-02-08 2021-02-09 2020-03-09
fiscalYear 2023 2022 2021 2020 2019
accountsReceivables 0 0 0 0 0
otherReceivables 32M 22M 21M 14M 0
prepaids 0 0 0 0 0
totalPayables 26M 19M 13M 12M 20M
otherPayables 0 0 0 0 0
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 1 778M 1 575M 1 359M 1 298M 1 034M

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH DCPH
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-10 2023-10-30 2023-08-09 2023-05-03 2022-11-03
acceptedDate 2024-05-10 07:27:06 2024-02-07 07:11:52 2023-10-30 07:11:54 2023-08-09 07:09:53 2023-05-03 07:10:05 2023-02-07 07:17:16 2022-11-03 07:09:23 2022-02-08 17:02:30 2021-02-09 16:09:37 2020-03-09 16:08:32
calendarYear 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -45M -195M -50M -49M -50M -179M -43M -300M -266M -192M
depreciationAndAmortization 2M 2M 465 000 571 000 608 000 3M 742 000 3M 2M 830 000
deferredIncomeTax 0 -7M -2M -2M 0 0 0 2M -2M 0
stockBasedCompensation 10M 51M 11M 13M 13M 52M 12M 46M 37M 20M
changeInWorkingCapital -20M -2M 9M -3M -13M -32M 9M 820 000 -14M 26M
accountsReceivables -878 000 -9M -4M -766 000 77 000 -2M 2M -7M -14M 0
inventory -918 000 -386 000 4M -4M -1M -7M 3M -10M -3M 0
accountsPayables -7M 8M 3M -1M 993 000 5M -3M 833 000 -8M 11M
otherWorkingCapital -11M 2M 7M 3M 188 000 -28M 6M 17M 11M 15M
otherNonCashItems 20M 4M 1M 1M -464 000 3M 469 000 7M 3M -4M
netCashProvidedByOperatingActivities -55M -147M -30M -39M -49M -153M -21M -241M -240M -149M
investmentsInPropertyPlantAndEquipment -146 000 -778 000 -62 000 -293 000 -360 000 -841 000 -573 000 -6M -5M -5M
acquisitionsNet 0 -13M -41M 0 0 33M 0 -4M 7000 0
purchasesOfInvestments -20M -323M -34M -106M -123M -323M -59M -335M -1 097M -817M
salesMaturitiesOfInvestments 83M 336M 75M 111M 88M 289M 53M 518M 1 132M 362M
otherInvestingActivites 63M 41M 0 0 0
netCashUsedForInvestingActivites 63M 41M 4M -35M -6M
debtRepayment 0 0 0 0 0
commonStockIssued 522 000 15M 0 135M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 522 000 968 000 0 -439 000 209 000
netCashUsedProvidedByFinancingActivities 522 000 16M 838 000 135M 209 000
effectOfForexChangesOnCash -847 000 910 000 -493 000 184 000 79 000 -145 000 -470 000 252 000 0 0
netChangeInCash 8M 19M 27M -33M 50M -22M -27M -49M 16M -173M
cashAtEndOfPeriod 91M 84M 108M 81M 115M 65M 83M 87M 136M 120M
cashAtBeginningOfPeriod 84M 65M 81M 115M 65M 87M 110M 136M 120M 294M
operatingCashFlow -55M -147M -30M -39M -49M -153M -21M -241M -240M -149M
capitalExpenditure -146 000 -778 000 -62 000 -293 000 -360 000 -841 000 -573 000 -6M -5M -5M
freeCashFlow -55M -147M -30M -39M -50M -154M -21M -247M -245M -154M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2024-02-07 2023-02-07 2022-02-08 2021-02-09 2020-03-09
fiscalYear 2023 2022 2021 2020 2019
otherInvestingActivities 13M -33M 4M -2M -441 000
netCashProvidedByInvestingActivities 13M -34M 177M 28M -461M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 0 0 0
netCommonStockIssuance 0 0 0 0 0
commonStockIssuance 150M 164M 9M 227M 432M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 152M 165M 15M 227M 436M
netCashProvidedByFinancingActivities 152M 165M 15M 227M 436M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-10-30 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-07 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-30 11:00 ET
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
2024-04-29 11:00 ET
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
2024-04-09 11:00 ET
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
2024-02-27 12:00 ET
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-02-06 12:00 ET
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-01 21:50 ET
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
2024-02-01 12:00 ET
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-18 16:13 ET
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2024-01-12 11:36 ET
GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe
2024-01-08 12:00 ET
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
2024-01-05 12:00 ET
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
2024-01-02 12:00 ET
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 12:00 ET
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
2023-11-07 12:00 ET
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-10-30 11:01 ET
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
2023-10-30 11:00 ET
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
2023-09-15 21:00 ET
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-18 20:05 ET
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-09 11:00 ET
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
2023-08-03 20:15 ET
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
2023-08-02 11:00 ET
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
2023-05-25 21:00 ET
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
2023-05-23 11:00 ET
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-05-08 11:00 ET
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
2023-05-03 11:00 ET
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
2023-04-26 11:00 ET
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
2023-04-19 11:00 ET
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
2023-03-14 21:53 ET
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
2023-03-14 21:32 ET
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-03-01 12:00 ET
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
2023-02-27 12:00 ET
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-02-07 12:00 ET
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
2023-02-02 12:00 ET
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-01-31 12:00 ET
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
2023-01-24 21:02 ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2023-01-24 21:01 ET
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
2023-01-20 00:56 ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2023-01-18 21:54 ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-01-03 21:02 ET
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
2023-01-03 21:01 ET
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
2023-01-03 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-01 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
2022-11-08 12:00 ET
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
2022-11-03 11:00 ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
2022-10-27 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
2022-09-11 10:30 ET
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
2022-09-10 13:00 ET
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
2022-09-01 11:00 ET
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
2022-08-19 20:05 ET
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-10 20:20 ET
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
2022-08-04 11:00 ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
2022-07-28 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
2022-07-15 20:20 ET
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-16 11:00 ET
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
2022-06-02 11:00 ET
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
2022-05-04 11:00 ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
2022-05-02 12:00 ET
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
2022-04-29 20:05 ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
2022-04-27 04:02 ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
2022-04-26 20:10 ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2022-04-12 19:50 ET
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
2022-03-09 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
2022-02-08 21:05 ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
2022-02-02 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
2022-02-01 12:00 ET
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
2022-01-24 22:00 ET
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
2022-01-10 12:00 ET
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
2022-01-03 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-21 13:44 ET
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2021-11-30 13:30 ET
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
2021-11-22 12:00 ET
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2021-11-05 11:00 ET
Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
2021-11-02 20:01 ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
2021-10-26 11:00 ET
Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
2021-10-12 11:00 ET
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2021-10-07 13:00 ET
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2021-09-17 12:17 ET
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
2021-09-17 11:00 ET
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
2021-09-10 11:00 ET
Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021
2021-09-02 11:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
2021-08-03 20:01 ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
2021-07-27 11:00 ET
Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
2021-06-30 20:01 ET
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
2021-06-04 13:00 ET
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-05-27 11:00 ET
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
2021-05-04 20:22 ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
2021-04-28 11:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit
2021-04-27 11:00 ET
Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
2021-03-31 08:57 ET
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
2021-03-02 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
2021-02-18 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-09 21:01 ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
2021-02-04 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
2021-02-02 12:00 ET
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
2021-01-11 12:00 ET
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
2021-01-05 12:23 ET
Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-11-30 12:00 ET
Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
2020-11-24 21:01 ET
Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-23 12:00 ET
The Boston Globe Names Deciphera a Top Place to Work for 2020
2020-11-11 12:01 ET
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
2020-11-11 12:00 ET
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
2020-11-10 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
2020-11-06 13:00 ET
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
2020-11-05 21:30 ET
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
2020-11-05 21:01 ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
2020-10-28 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
2020-09-18 11:00 ET
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
2020-09-17 11:00 ET
Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 
2020-08-17 20:30 ET
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
2020-08-06 12:40 ET
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
2020-08-04 20:05 ET
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
2020-07-29 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
2020-07-20 11:30 ET
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
2020-07-14 11:00 ET
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2020-07-02 20:01 ET
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
2020-06-22 11:00 ET
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2020-06-11 11:00 ET
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
2020-06-08 11:30 ET
Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
2020-05-29 12:05 ET
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program
2020-05-29 12:00 ET
Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
2020-05-27 11:00 ET
Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
2020-05-15 20:43 ET
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2020-05-05 20:01 ET
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results
2020-04-28 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020
2020-03-09 20:01 ET
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
2020-03-02 12:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020
2020-02-20 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-19 21:01 ET
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
2020-02-14 03:12 ET
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-02-12 21:14 ET
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-02-12 21:01 ET
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
2020-01-13 14:00 ET
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones
2020-01-06 12:00 ET
Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-16 12:00 ET
Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
2019-12-04 21:05 ET
Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors
2019-11-26 12:00 ET
Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman
2019-11-13 21:30 ET
Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting
2019-11-13 12:00 ET
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
2019-11-04 21:01 ET
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results
2019-10-29 16:30 ET
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2019-10-28 16:30 ET
Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2019-10-28 11:00 ET
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019
2019-10-16 20:34 ET
Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2019-10-02 11:00 ET
Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer
2019-09-30 13:06 ET
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
2019-09-25 11:00 ET
Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2024-05-10 00:00 ET
Deciphera Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-07 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Deciphera Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q4
SEC form 10
2023-10-30 07:11 ET
Deciphera Pharmaceuticals reported for 2023 q3
SEC form 8
2023-10-30 07:06 ET
Deciphera Pharmaceuticals published news for 2023 q3
SEC form 10
2023-10-30 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 07:09 ET
Deciphera Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-09 07:06 ET
Deciphera Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-03 16:20 ET
Deciphera Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-22 16:06 ET
Deciphera Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Deciphera Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-07 07:17 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-07 07:14 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-20 16:05 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-18 17:21 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-03 16:13 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-03 00:00 ET
Deciphera Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-03 07:09 ET
Deciphera Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-03 07:07 ET
Deciphera Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q3
SEC form 6
2022-09-12 07:30 ET
Deciphera Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-04 07:10 ET
Deciphera Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-04 07:08 ET
Deciphera Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-24 16:01 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 07:12 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-04 07:10 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Deciphera Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-27 21:03 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-26 16:01 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-26 07:36 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 8
2022-04-26 00:00 ET
Deciphera Pharmaceuticals published news for 2022 q1
SEC form 6
2022-02-11 16:02 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-11 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-08 17:13 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-08 17:02 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-08 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-08 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-24 17:06 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 07:14 ET
Deciphera Pharmaceuticals published news for 2021 q4
SEC form 6
2021-11-30 08:41 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-22 07:25 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-10 16:34 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-05 07:10 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-02 16:11 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-02 16:07 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-29 16:01 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-17 16:01 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-17 07:07 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 16:12 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 16:07 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-25 16:00 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 16:19 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 16:16 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 16:05 ET
Deciphera Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-31 07:54 ET
Deciphera Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-09 16:09 ET
Deciphera Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-09 16:06 ET
Deciphera Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 07:15 ET
Deciphera Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-30 07:12 ET
Deciphera Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-12 07:30 ET
Deciphera Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 16:24 ET
Deciphera Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 16:10 ET
Deciphera Pharmaceuticals published news for 2020 q3